NIIMBL Demos Closed-Loop Continuous Processing
Projects at the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) are successfully integrating continuous upstream processing platforms with closed-loop control of critical quality attributes (CQAs). The work demonstrates the growing maturity of combining real-time analytics with digital process control. One approach under evaluation involves regenerating spent media to improve productivity and sustainability.
- The University of Massachusetts Lowell is a key academic partner in a NIIMBL project aiming to create a scalable, economically-optimized perfusion system that automates control over productivity and Critical Quality Attributes (CQAs). - A significant hurdle to the widespread adoption of continuous manufacturing is the limited number of contract development and manufacturing organizations (CDMOs) with the necessary capabilities, which particularly constrains smaller biotech firms that depend on them. - Digital twin technology is a core component of the Industry 4.0 shift in biomanufacturing; it uses real-time data from sensors and control systems to simulate, monitor, and optimize production processes, enabling predictive maintenance and proactive quality control. - The NIIMBL Process Intensification program is focused on five key areas: standardization, end-to-end automated CQA control, multivariate sensors, advanced control strategies, and bioprocess modeling to enable real-time, data-driven decision-making. - Since its launch in 2017, NIIMBL has awarded 123 projects led by its members, amounting to an approximate value of $111 million, to advance biopharmaceutical manufacturing. - A major challenge in implementing continuous manufacturing is the integration of downstream unit operations, which requires precise synchronization of residence times and flow rates, and advanced automated process-control strategies to manage potential disruptions. - The global pharmaceutical CDMO market is projected to grow at a CAGR of around 6.9% to 8.7%, with expectations of reaching approximately $368.7 billion by 2034. - Key technological roadblocks for the broad adoption of continuous bioprocessing include the full implementation of Quality by Design (QbD), seamless integration of upstream and downstream technologies, and robust data and knowledge management systems.
